Back to the future: the 'old-fashioned' way to new medications for neurodegeneration
Top Cited Papers
- 1 July 2004
- journal article
- review article
- Published by Springer Nature in Nature Medicine
- Vol. 10 (S7), S51-S57
- https://doi.org/10.1038/nrn1435
Abstract
Nature Medicine and Nature Reviews Neuroscience are proud to present a special supplement devoted to Neurodegenerative Diseases. Written by leaders in the field, the supplement provides an authoritative update on the cellular processes that are common to the most frequently observed diseases of the brain, and points to some of the approaches that are being pursued to treat these devastating conditions. Thanks to the sponsorship of AstraZeneca, the entire conents of this website will be freely available to the entire community for a period of three months.Keywords
This publication has 39 references indexed in Scilit:
- Folding proteins in fatal waysNature, 2003
- Therapeutic approaches to protein-misfolding diseasesNature, 2003
- The Non-cyclooxygenase Targets of Non-steroidal Anti-inflammatory Drugs, Lipoxygenases, Peroxisome Proliferator-activated Receptor, Inhibitor of κB Kinase, and NFκB, Do Not Reduce Amyloid β42 ProductionJournal of Biological Chemistry, 2003
- A new model for drug discovery – meeting our societal obligationDrug Discovery Today, 2003
- Biotech Thinking Comes to Academic Medical CentersScience, 2003
- γ‐Secretase/presenilin inhibitors for Alzheimer's disease phenocopy Notch mutations inDrosophilaThe FASEB Journal, 2002
- Genetics of Parkinson's disease and biochemical studies of implicated gene products: CommentaryCurrent Opinion in Cell Biology, 2002
- ACT and UCH‐L1 polymorphisms in Parkinson's disease and age of onsetMovement Disorders, 2002
- A Drosophila model of Parkinson's diseaseNature, 2000
- Release of Excess Amyloid β Protein from a Mutant Amyloid β Protein PrecursorScience, 1993